Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Type 2 diabetes mellitus compromises the survival of diffuse large B-cell lymphoma patients treated with (R)-CHOP - the PLRG report.
Drozd-Sokolowska J, Zaucha JM, Biecek P, Giza A, Kobylinska K, Joks M, Wrobel T, Kumiega B, Knopinska-Posluszny W, Spychalowicz W, Romejko-Jarosinska J, Fischer J, Wiktor-Jedrzejczak W, Dlugosz-Danecka M, Giebel S, Jurczak W. Drozd-Sokolowska J, et al. Among authors: joks m. Sci Rep. 2020 Feb 26;10(1):3517. doi: 10.1038/s41598-020-60565-7. Sci Rep. 2020. PMID: 32103128 Free PMC article. Clinical Trial.
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study.
Jurczak W, Szmit S, Sobociński M, Machaczka M, Drozd-Sokołowska J, Joks M, Dzietczenia J, Wróbel T, Kumiega B, Zaucha JM, Knopińska-Posłuszny W, Spychałowicz W, Prochwicz A, Drohomirecka A, Skotnicki AB. Jurczak W, et al. Among authors: joks m. Int J Cardiol. 2013 Oct 15;168(6):5212-7. doi: 10.1016/j.ijcard.2013.08.033. Epub 2013 Aug 15. Int J Cardiol. 2013. PMID: 23998543
Primary cutaneous indolent B-cell lymphomas - a retrospective multicenter analysis and a review of literature.
Olszewska-Szopa M, Sobas M, Laribi K, Bao Perez L, Drozd-Sokołowska J, Subocz E, Joks M, Zduniak K, Gajewska M, de Nalecz AK, Romejko-Jarosińska J, Kumiega B, Waszczuk-Gajda A, Wróbel T, Czyz A. Olszewska-Szopa M, et al. Among authors: joks m. Acta Oncol. 2021 Oct;60(10):1361-1368. doi: 10.1080/0284186X.2021.1956689. Epub 2021 Aug 4. Acta Oncol. 2021. PMID: 34346830 Review.
Role of rituximab in the first-line therapy of high-risk diffuse large B-cell lymphoma: a retrospective analysis by the Polish Lymphoma Research Group.
Jurczak W, Ochrem B, Giza A, Zimowska-Curyło D, Górecki T, Boguradzki P, Knopińska-Posłuszny W, Stella-Hołowiecka B, Walewski J, Joks M, Wróbel T, Zaucha JM. Jurczak W, et al. Among authors: joks m. Pol Arch Med Wewn. 2015;125(10):741-8. doi: 10.20452/pamw.3113. Epub 2015 Sep 3. Pol Arch Med Wewn. 2015. PMID: 26334344 Free article.
Acute decompensated heart failure as a reason of premature chemotherapy discontinuation may be independent of a lifetime doxorubicin dose in lymphoma patients with cardiovascular disorders.
Szmit S, Jurczak W, Zaucha JM, Długosz-Danecka M, Sosnowska-Pasiarska B, Chmielowska E, Joks M, Drozd-Sokołowska J, Knopińska-Posłuszny W, Spychałowicz W, Kumiega B, Charliński G, Morawska M, Słomian G. Szmit S, et al. Among authors: joks m. Int J Cardiol. 2017 May 15;235:147-153. doi: 10.1016/j.ijcard.2017.02.073. Epub 2017 Feb 22. Int J Cardiol. 2017. PMID: 28268088
Characteristics and outcomes of patients with multiple myeloma aged 21-40 years versus 41-60 years: a multi-institutional case-control study.
Jurczyszyn A, Nahi H, Avivi I, Gozzetti A, Niesvizky R, Yadlapati S, Jayabalan DS, Robak P, Pika T, Andersen KT, Rasche L, Mądry K, Woszczyk D, Raźny M, Usnarska-Zubkiewicz L, Knopińska-Posłuszny W, Wojciechowska M, Guzicka-Kazimierczak R, Joks M, Grosicki S, Ciepłuch H, Rymko M, Vesole DH, Castillo JJ. Jurczyszyn A, et al. Among authors: joks m. Br J Haematol. 2016 Dec;175(5):884-891. doi: 10.1111/bjh.14328. Epub 2016 Sep 29. Br J Haematol. 2016. PMID: 27682187 Free article.
Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.
Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA. Dytfeld D, et al. Among authors: joks m. Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059. Oncotarget. 2016. PMID: 27527861 Free PMC article.
The Outcomes of Ponatinib Therapy in Patients With Chronic Myeloid Leukemia Resistant or Intolerant to Previous Tyrosine Kinase Inhibitors, Treated in Poland Within the Donation Program.
Sacha T, Szczepanek E, Dumnicka P, Góra-Tybor J, Niesiobędzka-Krężel J, Prejzner W, Wasilewska E, Kłoczko J, Ciepłuch H, Makowska W, Patkowska E, Wasilewska J, Bober G, Kopera M, Wichary R, Kroll-Balcerzak R, Gromek T, Wach M, Rudkowska-Kazanowska A, Świniarska M, Paczkowska E, Biernat M, Joks M, Oller M, Kasza R, Kostyra A, Gil J, Grzybowska-Izydorczyk O. Sacha T, et al. Among authors: joks m. Clin Lymphoma Myeloma Leuk. 2022 Jun;22(6):405-415. doi: 10.1016/j.clml.2021.11.012. Epub 2021 Nov 20. Clin Lymphoma Myeloma Leuk. 2022. PMID: 34933827 Free article.
25 results